---
title: "Dian Diagnostics Group Co.,Ltd. (300244.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/300244.SZ.md"
symbol: "300244.SZ"
name: "Dian Diagnostics Group Co.,Ltd."
industry: "Health Care Services"
---

# Dian Diagnostics Group Co.,Ltd. (300244.SZ)

| Item | Detail |
|------|--------|
| Industry | Health Care Services |
| Location | CN Market |
| Website | [www.dazd.cn](https://www.dazd.cn) |

## Company Profile

Dian Diagnostics Group Co.,Ltd. provides integrated medical diagnostics solutions with independent diagnostic services in China. The company offers laboratory supplies and kits; AI-assisted digital pathology diagnosis solutions, such as nucleic acid extraction and purification system, automatic liqu...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:09.000Z

**Overall: D (0.63)**

**Industry**: Health Care Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 6 / 8 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -15.12% |  |
| Net Profit YoY | -366.10% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 2.33 |  |
| Dividend Ratio | 1.01% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 15.07B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 10.50B |  |


**Multi Score**: D

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -6.38% | D |
| Profit Margin | -4.11% | D |
| Gross Margin | 31.84% | C |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -15.12% | E |
| Net Profit YoY | -366.10% | E |
| Total Assets YoY | -13.53% | E |
| Net Assets YoY | -8.48% | D |

#### Cash Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -2434.63% | E |
| OCF YoY | -15.12% | E |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.66 | B |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 41.25% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Dian Diagnostics Group Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-6.38%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-4.11%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "31.84%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-15.12%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-366.10%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-13.53%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-8.48%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "E",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-2434.63%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-15.12%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.66",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "41.25%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | TC Medical (SH.600763) | B | C | C | B | C | B |
| 02 | Meinian Onehealth (SZ.002044) | C | C | C | D | B | C |
| 03 | NJXB (SH.600682) | C | D | D | B | B | C |
| 04 | Zhongjin Irradiation (SZ.300962) | B | C | D | A | C | C |
| 05 | HESH (SZ.301103) | C | C | C | A | B | C |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -34.94 | 8/8 | - | - | - |
| PB | 2.33 | 4/8 | 1.64 | 1.52 | 1.41 |
| PS (TTM) | 1.44 | 2/8 | 0.98 | 0.89 | 0.80 |
| Dividend Yield | 1.01% | 2/8 | 5.30% | 4.23% | 1.50% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-10T16:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 4 | 50% |
| Overweight | 0 | 0% |
| Hold | 3 | 38% |
| Underweight | 0 | 0% |
| Sell | 1 | 13% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 24.12 |
| Highest Target | 21.00 |
| Lowest Target | 8.50 |

## References

- [Company Overview](https://longbridge.com/en/quote/300244.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/300244.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/300244.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.